You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Pharmaceuticals Policy and Law - Volume 6, issue 0

Purchase individual online access for 1 year to this journal.

Price: EUR 100.00
The new international review, Pharmaceuticals Policy and Law, appears with the aim of studying and evaluating the legal status of medicinal products in the European Union, and its implications in other markets such as the USA and Japan, without neglecting the specific problems of developing countries.

Pharmaceuticals Policy and Law intends to participate in the process of world convergence of pharmaceutical legislation helped by a network of academic centers specializing in pharmaceutical law, without omitting a scientific, economic and social approach to medicinal products.

The specificity of medicinal products conditions their legal status. Legislation regulating other goods cannot be applied to them. To begin with, they are the result of scientific and technical innovation. Research policies determine their progress. The pharmaceutical industry is, by nature, multinational. But, next to these global trends, different traditions still remain at a national level. Within the EU, barriers to free trade in medicinal products still remain despite more than thirty years of harmonisation. The social dimension of medicinal products is complex and very significant in the preoccupations of our societies. Patenting is essential but not sufficient. The life-cycle of medicinal products is protected by professional responsibility, required in the general concept of health safety. It is important to remember their ethical dimension, including research and innovation in new fields such as genetic manipulation and biotechnology, which requires social consent to preserve human dignity and fundamental rights.
results per page

Opportunities and challenges for the self-care industry after the revision

Authors: Cranz, Hubertus

Article Type: Research Article

Citation: Pharmaceuticals, Policy and Law, vol. 6, no. 0, pp. 95-103, 2005

Price: EUR 27.50

Implications of the new directive on traditional herbal medicinal products

Authors: Nisticò, Giuseppe

Article Type: Research Article

Citation: Pharmaceuticals, Policy and Law, vol. 6, no. 0, pp. 105-107, 2005

Price: EUR 27.50

Patent term extension strategies in the pharmaceutical industry

Authors: Bhat, Vasanthakumar N.

Article Type: Research Article

Abstract: The purpose of this paper is to discuss patent term extension strategies for pharmaceutical companies in the United States. Market exclusivity acquired through patents can yield higher prices and profits for pharmaceutical products. Therefore, pharmaceutical companies use a variety of strategies to increase market exclusivity of their products. Some of the strategies discussed in this paper include one-year extension of time to file for patent under the Paris convention, patent term restoration allowed by the … Show more

Keywords: patents, generics, pharmaceuticals, market exclusivity, Paris convention

Citation: Pharmaceuticals, Policy and Law, vol. 6, no. 0, pp. 109-122, 2005

Price: EUR 27.50

Some problematical aspects of the European regulation of medicinal products 2004

Authors: Ma Suñé Arbussà, José

Article Type: Research Article

Citation: Pharmaceuticals, Policy and Law, vol. 6, no. 0, pp. 123-137, 2005

Price: EUR 27.50
Show more